Advanced Malignant Solid Tumor
Conditions
Keywords
Solid Tumor
Brief summary
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG161, and recommended dose of VG161 for Phase II trials.
Detailed description
The trial will be conducted in 7 dose ascending cohorts, including 3 single dose accelerated titration design pilots and 4 multiple dose escalation groups. Descriptive statistics will be used to summarize all data.
Interventions
Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
Sponsors
CNBG-Virogin Biotech (Shanghai) Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Males or females aged within 18 to 80 years. 2. Subject with late stage carcinoma which is refractory/relapsed after and/or intolerant of standard therapies or for which no standard therapy exists. 3. There is at lease one injectable tumor lesion that meet the requirements of the assigned dose level. The superficial lesions are preferred, and the deep lesions that can be injected under the guidance of B ultrasound or computed tomography (CT) scan can also be selected. 4. Eastern Cooperative Oncology Group (ECOG) scores 0 or 1. 5. Life expectancy is at least 3 months. 6. Required organ function: 1\) Hematology blood (no blood transfusion or colony stimulating factor treatment within 14 days): Absolute neutrophil count (ANC)≥1.5×10\^9L, Platelets ( PLT)≥75×10\^9L, hemoglobin (Hb)≥85g/L; 2) Liver function: Total Serum bilirubin (TBIL)≤1.5×ULN (the upper limit of the reference range), Alanine aminotransferase (ALT)≤3×ULN, aspartate aminotransferase (AST)≤3×ULN (acceptable for patients with liver metastasis or liver cancer: TBIL≤5×ULN, AST≤5×ULN, ALT≤5×ULN); 3) Renal function: Serum creatinine≤1.5×ULN, and creatinine clearance≥50 ml/min (calculated per Cockcroft-Gault formula); 4) Coagulation function: activated partial thromboplastin time (APTT)≤1.5×ULN, international standardized ratio (INR)≤1.5×ULN. 7\. Subjects of childbearing potential (male and female) must agree to use a reliable contraceptive method (hormone or barrier method or abstinence) during the study and for at least 90 days following the last dose; females of childbearing potential must have a negative blood or urine pregnancy test within 7 days of study enrollment. 8\. Signed written informed consent.
Exclusion criteria
1. Subject in prior anti-tumor therapies such as chemotherapy, radiotherapy, biotherapy, endocrinotherapy, targeted therapy, immunotherapy within 4 weeks of study treatment initiation. 2. Participation in clinical trials of any other investigational agents within 4 weeks of study treatment initiation. 3. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks of study treatment initiation. 4. Patients who received systemic treatment with either corticosteroids ( \>10 mg/ daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study treatment initiation. 5. Subjects with any ≥Grade 1 toxicity (as per NCI CTC AE Version 5.0) related to prior anti-cancer therapy (except for toxicity that the investigator assessed to be no safety risk, such as alopecia.). 6. Subjects with any uncontrolled active Central Nervous System (CNS) metastasis or meningeal metastasis with clinical symptoms. 7. Seronegative for Herpes Simplex Virus (HSV) (HSV-1IgG and HSV-1IgM). 8. Subjects with the relapse of HSV infection and relevant clinical manifestations, such as lip herpes, herpes keratitis, herpes dermatitis, and genital herpes. 9. Subjects with other uncontrolled active infections. 10. Known history of immunodeficiency and test positive of human immunodeficiency virus (HIV). 11. Active infection of hepatitis B (HBV) (hepatitis b virus titer higher than the detection limit or those requiring antiviral therapy), or hepatitis C virus (HCV). 12. History of severe cardiovascular disease: 1)Ventricular arrhythmias requiring clinical intervention; 2)QTc interval \>480 ms; 3)Acute coronary syndrome, congestive heart failure, stroke or other cardiovascular events of III grade or above within 6 months; 4)The cardiac function grade≥II or left ventricular ejection fraction (LVEF) \<50% per the New York Heart Association (NYA); 5)Uncontrolled hypertension. 13. Subjects with active or past autoimmune diseases that are likely to recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.); acceptable for patients with clinically stable autoimmune thyroiditis. 14\. Subjects with any prior ≥Grade 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent. 15\. known to have alcohol or drug dependence. 16. Persons with mental disorders or poor compliance. 17. Pregnant or lactating women. 18. Subjects with any significant unrelated systemic illness that to the investigator's opinion would compromise the subject's eligibility to participate the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MTD/RP2D | 1 month | MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II) |
| Occurence of DLT | 1 month | Occurence of DLT (Dose Limiting Toxicity) |
| Numbers of DLT | 1 month | Numbers of DLT (Dose Limiting Toxicity) |
| Occurence of AE and SAE（NCI CTCAE 5.0） | 7 months | Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0） |
| Frequency of AE and SAE（NCI CTCAE 5.0） | 7 months | Frequency of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0） |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CD3+, CD4+, CD8+ | 7 months | Concentration of CD3+, CD4+, CD8+ |
| IL15 | 7 months | Concentration of IL15 |
| Tmax(h) | At the end of Cycle 1 (each cycle is 28 days) | Time to peak |
| Existence of Biomarkers | 4 months | PD-L1, Nectin2, HVEM |
| PD-L1, PD-1 | 7 months | Concentration of PD-L1, PD-1, |
| Cmax(copies/ugDNA) | At the end of Cycle 1 (each cycle is 28 days) | Maximum concentration |
| ORR | 7 months | Evaluate Objective Response Rate by RECIST 1.1. |
| DCR | 7 months | Evaluate Disease Control Rate by RECIST 1.1. |
| mPFS | 7 months | Evaluate medium Progression Free Survival by RECIST 1.1. |
Countries
China
Contacts
Primary ContactJin Li, doctor
Outcome results
None listed